The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson’s disease Original paper
-
Dr. Umar
Read MoreClinical Pharmacist and Clinical Pharmacy Master’s candidate focused on antibiotic stewardship, AI-driven pharmacy practice, and research that strengthens safe and effective medication use. Experience spans digital health research with Bloomsbury Health (London), pharmacovigilance in patient support programs, and behavioral approaches to mental health care. Published work includes studies on antibiotic use and awareness, AI applications in medicine, postpartum depression management, and patient safety reporting. Developer of an AI-based clinical decision support system designed to enhance antimicrobial stewardship and optimize therapeutic outcomes.
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease—four years before the first published case study.
What was studied?
This original research investigated the diagnostic value of intestinal mucosal oligomeric α-synuclein (OSyn) and the relationship between mucosal α-synuclein (αSyn) expression and mucosal microbiota composition in Parkinson’s disease (PD). The study aimed to resolve uncertainties about whether intestinal mucosal αSyn could serve as an early biomarker for PD, given that αSyn aggregation is a hallmark of the disease not only in the brain but also in the enteric nervous system. Using gastrointestinal endoscopy, duodenal and sigmoid mucosal samples were collected from participants. Multiplex immunohistochemistry (mIHC) was employed to detect total, phosphorylated, and oligomeric αSyn simultaneously, while next-generation 16S rRNA amplicon sequencing was used to characterize the mucosal microbiota. The study further explored whether the distribution and ratios of different αSyn species—especially the OSyn/αSyn ratio—correlated with distinct microbial signatures, potentially forming the basis for a microbiome signature database relevant to PD diagnosis and pathogenesis.
Who was studied?
The study involved a total of 41 participants: 19 patients clinically diagnosed with Parkinson’s disease (Hoehn and Yahr stage <5) and 22 age-matched healthy controls with no neurodegenerative diseases. All participants were recruited from Beijing Hospital and provided written informed consent. Gastrointestinal endoscopies were performed to obtain duodenal and sigmoid mucosal biopsies. Notably, duodenal mucosal specimens from 7 healthy controls and 10 PD patients, and sigmoid mucosal specimens from 21 healthy controls and 19 PD patients, were used for mIHC analysis. For microbiota sequencing, post-quality control, duodenal mucosal samples from 7 controls and 7 PD patients, and sigmoid mucosal samples from 18 controls and 17 PD patients, were analyzed. The cohort was balanced in terms of sex and age between groups, and all procedures were conducted under strict ethical guidelines.
Most important findings
The study revealed several key findings with direct relevance to the identification of microbiome signatures in PD:
| Topic | Details |
|---|
| α-Synuclein distribution & diagnostic value | In PD, oligomeric α-synuclein (OSyn) in sigmoid mucosa shifts from the epithelial membrane (controls) to cytoplasm, acinar lumen, and stroma. The OSyn/αSyn ratio is markedly higher in PD and shows near-perfect diagnostic performance (ROC AUC = 0.997), supporting it as a strong preclinical PD biomarker. |
| Microbial composition shifts | Mucosal microbiota differ between PD and controls, especially in the duodenum. PD duodenal mucosa shows higher proinflammatory Proteobacteria (Gammaproteobacteria: Burkholderiales, Burkholderiaceae, Oxalobacteraceae, Ralstonia, Massilia) and Lactococcus, with reduced Kiloniellales, Flavobacteriaceae, and CAG56. In sigmoid mucosa, PD patients have more Prevotellaceae and Bifidobacterium longum, and fewer Thermoactinomycetales and Thermoactinomycetaceae. |
| Correlations between αSyn and microbiota | In duodenal mucosa, the OSyn/αSyn ratio positively correlates with Proteobacteria, Gammaproteobacteria, Burkholderiales, Pseudomonadales, Burkholderiaceae, and Ralstonia. In sigmoid mucosa, higher OSyn/αSyn is linked to lower microbial diversity (Chao1, observed OTUs) and reduced Chloroflexi, Gemmatimonadota, Nitrospirota, and Myxococota, tying pathological αSyn aggregation to loss of microbial diversity. |
| Functional predictions | Predicted functions indicate enrichment of glutathione S-transferase and branched-chain amino acid transport pathways in PD duodenal mucosa, with other transport systems enriched in sigmoid mucosa, consistent with altered gut–brain axis signaling and neuroinflammatory mechanisms in PD. |
Key implications
This study provides compelling evidence that the OSyn/αSyn ratio in sigmoid mucosa is a highly promising, minimally invasive biomarker for early PD diagnosis. The findings also demonstrate that PD is associated with proinflammatory shifts in the duodenal mucosal microbiota—particularly increased Proteobacteria—supporting the hypothesis that gut dysbiosis contributes to PD pathogenesis via the microecology-gut-brain axis. The strong correlation between specific microbial taxa and αSyn aggregation highlights the potential for microbiome-based diagnostic and therapeutic strategies. Additionally, the work emphasizes the importance of mucosal (rather than fecal) microbiota profiling for disease-specific signatures, as mucosal communities may better reflect local pathophysiology. These insights could inform the development of microbiome signatures databases and guide future interventions targeting gut microbiota to modify PD progression.
Citation
Shi J, Wang Y, Chen D, Xu X, Li W, Li K, He J, Su W, Luo Q. The alteration of intestinal mucosal α‑synuclein expression and mucosal microbiota in Parkinson’s disease. Applied Microbiology and Biotechnology. 2023;107:1917–1929. doi:10.1007/s00253-023-12410-w